We then utilized a curated human ovarian cancer Tissue Microarray (TMA), containing WT, BRCA1-mutated, and BRCA2-mutated ovarian serous carcinoma sections to test whether the RAD18-dependent fork recovery pathway is upregulated in BRCA1 mutant tumors by immunohistochemical (IHC) analysis. This evidence concerns the gene BRCA2 and ovarian cancer.